Reaction

Mean Cell Haemoglobin Concentration Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,642 reports · 51 co-occurring drugs

As of the last recalculation, Mean Cell Haemoglobin Concentration Decreased appears in 1,642 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is CLOZAPINE (PRR 50.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Clozapine38550.550.6
Alemtuzumab7350.050.2
Dimenhydrinate3643.843.9
Ado-Trastuzumab Emtansine1827.427.4
Entecavir1213.113.1
Methylprednisolone Sodium Succinate4512.612.6
Standardized Senna Concentrate1212.212.2
Candesartan3311.912.0
Rosuvastatin Calcium2611.911.9
Valproic Acid2911.911.9
Fesoterodine Fumarate1011.811.8
Terazosin Hydrochloride811.511.5
Infliximab-Dyyb2611.411.5
Tiotropium Bromide Inhalation Spray1011.411.4
Aripiprazole Oral3611.311.3
Aripiprazole Orally Disintegrating3611.311.3
Calcitriol Capsules 0.25 Mcg1710.910.9
Calcitriol Capsules 0.5 Mcg1710.910.9
Bisacodyl Suppositories1110.810.9
Dalteparin Sodium910.810.8
Biscodyl1110.710.8
Calcitriol1710.710.7
Lithium Carbonate1410.510.5
Ribociclib2510.210.2
Felodipine Extended-Release Tablets910.110.1
Felodipine910.110.1
Letrozole Tablets3710.010.0
Niraparib179.89.8
Eculizumab409.59.5
Nicotine Polacrilex Mini119.39.4
Nicotine Polarilex119.39.4
Methoxy Polyethylene Glycol-Epoetin Beta89.29.2
Oxybutynin Chloride68.78.7
Goserelin98.58.5
Bosutinib68.58.5
Letrozole408.48.4
Instalax Polyethylene Glycol 335088.28.2
Polyethylene Glycol 40088.08.0
Amphetamine46.16.1
Desoximetasone96.06.0
Tofacitinib Citrate65.85.8
Insulin Degludec105.45.4
Asfotase Alfa45.15.1
Palbociclib354.74.7
Ravulizumab54.74.7
Nicotine Polacrilex144.74.7
Fingolimod Hcl304.54.5
Tolvaptan54.44.4
Somatropin234.04.0
Crizotinib44.04.0
Pirfenidone82.52.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.